Related Experiment Video
Updated: Jun 16, 2026
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Microglial CLEC7A restrains amyloid beta plaque pathology in a mouse model of Alzheimer's disease
Aman Mangalmurti1,2,3,4, Kristine E Zengeler1,4, Ava Hollis1,4
1Center for Brain Immunology and Glia (BIG), Department of Neuroscience, University of Virginia, Charlottesville, Virginia, USA.
Introduction:
CLEC7A is a surface receptor that is highly upregulated on microglia in many Alzheimer's disease (AD) models. Little is known about the role that microglial CLEC7A signaling plays in AD-related pathogenesis.
Methods:
We utilized an inducible, central nervous system (CNS) macrophage-specific knockout of Clec7a to evaluate the role of CLEC7A in the 5xFAD mouse model of AD at 5 months of age. We used immunofluorescence microscopy, single-nuclei RNA sequencing, along with biochemical assays, to evaluate plaque burden, microglial activity, and neuronal health.
Results:
CNS macrophage-targeted deletion of CLEC7A in 5xFAD mice led to a twofold increase in plaque burden, exacerbated neuritic dystrophy, and altered the expression of neuronal health genes, but did not appreciably impact microglial activation, plaque engulfment, or disease-associated microglia acquisition.
Discussion:
These findings identify protective roles for CLEC7A in AD-related amyloidosis and suggest that CLEC7A-targeting therapeutics may offer promising strategies for treatment of AD.
Highlights:
Conditional loss of CLEC7A in central nervous system (CNS) macrophages of 5xFAD mice results in increased amyloid beta deposition. Loss of CLEC7A does not alter the disease-associated microglia transcriptional program or affect the recruitment of microglia to plaque surfaces. Exacerbation of amyloid deposition with loss of CNS-macrophage CLEC7A is associated with worsened neuronal health highlighted by increased neuritic dystrophy.
Insights
Deleting CLEC7A in brain immune cells of Alzheimer's disease (AD) models worsened amyloid plaque buildup and neuronal damage. This suggests CLEC7A plays a protective role in AD pathogenesis, offering a potential therapeutic target.
Area of Science:
- Neuroscience
- Immunology
- Genetics
Background:
- C-type lectin domain family 7 member A (CLEC7A) is upregulated on microglia in Alzheimer's disease (AD) models.
- The specific role of microglial CLEC7A signaling in AD pathogenesis remains largely unknown.
Purpose of the Study:
- To investigate the function of CLEC7A in microglia within the context of AD.
- To determine the impact of CLEC7A deletion on amyloid pathology and neuronal health in a mouse model of AD.
Main Methods:
- Utilized an inducible, CNS macrophage-specific knockout of Clec7a in the 5xFAD mouse model of AD.
- Employed immunofluorescence microscopy, single-nuclei RNA sequencing, and biochemical assays.
- Assessed plaque burden, microglial activity, and neuronal health at 5 months of age.
Main Results:
- CNS macrophage-targeted deletion of CLEC7A resulted in a twofold increase in plaque burden.
- Neuritic dystrophy was exacerbated, and neuronal health gene expression was altered.
- Microglial activation, plaque engulfment, and disease-associated microglia acquisition were not significantly impacted.
Conclusions:
- CLEC7A exhibits protective roles in AD-related amyloidosis.
- Conditional loss of CLEC7A in CNS macrophages exacerbates amyloid deposition and worsens neuronal health.
- Targeting CLEC7A may represent a promising therapeutic strategy for AD treatment.
